New antibiotic treatment for infected bone fractures
Official title: A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
Funded at Biovinc, LLC · NIH-11252269 · Data updated 2026-11-12
This study is testing a new way to help people with infected bone fractures heal better by using special antibiotics that are delivered right to the infection site, making recovery easier and reducing the risk of serious complications.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biovinc, LLC NIH-funded |
| Lab location | 1 site (Santa Barbara, United States) |
| Project start | April 22, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $992,575 |
| NIH project number | 5R44AI175069-03 |
| Project ID | NIH-11252269 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced bone fractures that are infected or at risk of infection.
✕Less likely to help
Patients with fractures that are not infected or those who do not have complications related to fracture healing may not benefit from this research.
What this research studies
This research focuses on developing a novel antibiotic therapy specifically designed to target infections in bone fractures. It aims to improve healing outcomes for patients suffering from infected fractures, which can lead to severe complications such as nonunion or amputation. The approach utilizes bisphosphonates, which are known for their strong affinity to bone, to deliver antibiotics directly to the site of infection. By doing so, the therapy seeks to reduce the burden of infections and enhance the healing process for affected patients.
Why it matters
Potential benefit: If successful, this research could significantly improve healing rates and reduce complications for patients with infected fractures.
How similar studies have gone: Other research has shown promise in using targeted antibiotic therapies for bone infections, indicating potential success for this novel approach.
Where this research is happening
-
Biovinc, LLC
Santa Barbara, United States Active
Researchers
- Principal investigator: Ebetino, Frank H. — Biovinc, LLC
- Study coordinator: Ebetino, Frank H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.